KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.

Sebastian Wolf, Youxin Chen, Xiaorong Li, Masahiko Shimura, Taiji Sakamoto, Charles C Wykoff, Andres Emanuelli, Hani Salehi-Had, Kang Yan, Lidija Kovacic, Yongsoo Kim

JAMA Ophthalmol 144(6) 500-507

PMID42024409
PMCIDPMC13107309
DOI10.1001/jamaophthalmol.2026.1008
发表日期2026-04-23
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:AI 判定为 other;Figure 3.:AI 判定为 other。
摘要

摘要

IMPORTANCE: CONDOR (Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy) is a large-scale, company-sponsored randomized clinical trial to assess the unique 6-week (loading) and 12-week (maintenance) brolucizumab dosing regimen in proliferative diabetic retinopathy (PDR). OBJECTIVE: To assess the efficacy and safety of brolucizumab, 6 mg, compared with panretinal laser photocoagulation (PRP) in eyes with PDR. DESIGN, SETTING, AND PARTICIPANTS: CONDOR is a 96-week, 2-arm, single-masked, multicenter, phase 3 randomized clinical trial conducted across 16 countries at 152 sites. Data were analyzed from December 4, 2020 (first participant first visit), to October 30, 2023 (cutoff date). Patients with diabetes and PDR diagnosis and no previous PRP treatment in the study eye were eligible for inclusion. INTERVENTION: Patients randomized to receive brolucizumab, 6 mg, received 3 loading doses every 6 weeks, followed by every 12 weeks, with the option from week 48 onward to extend the treatment interval by 6 weeks at a time up to 24 weeks based on disease activity. Patients randomized to PRP received treatment in 1 to 4 sessions up to week 12, followed by additional PRP treatment as needed. MAIN OUTCOMES AND MEASURES: The primary outcome measure was change from baseline in best-corrected visual acuity (BCVA) at week 54. Secondary outcomes included change in DR progression, prevention of center-involved diabetic macular edema, change in Diabetic Retinopathy Severity Score levels, and safety. RESULTS: A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs -4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P < .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P < .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm. CONCLUSIONS AND RELEVANCE: In the CONDOR randomized clinical trial, brolucizumab was superior to PRP in preserving visual acuity and may be a viable treatment alternative to PRP monotherapy for patients with PDR. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04278417.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Study Participant Flow Diagram PRP indicates panretinal photocoagulation. a 8.9% of Patients missed the week 54 visit but remained in the study at the week 54 cutoff. b 7.9% of Patients missed the week 54 visit but remained in the study at the week 54 cutoff.
非 KM Figure
Figure 2.Line Graph Showing Least-Square Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Up to Week 54 Mean (SD) BCVA letter score at baseline was 77.2 (10.23) (20/32 Snellen equivalent) in the brolucizumab, 6 mg, arm and 77.0 (10.87) (20/32 Snellen equivalent) in the panretinal photocoagulation (PRP) arm. Missing data were imputed with last observation carried forward. However, 10 patients (5 in each arm) were without baseline Diabetic Retinopathy Severity Score level, which was used as covariate in the analysis of covariance mode, hence why the number of patients reduced to 342 and 337 in the brolucizumab and PRP arms, respectively.
非 KM Figure
Figure 3.Bar Graph Showing Percentage of Study Participants With No Proliferative Diabetic Retinopathy at a Specific Visit PRP indicates panretinal photocoagulation.
非 KM Figure